Towa Pharmaceutical Co Ltd

Towa Pharmaceutical Co Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,029.00
  • Today's Change-13.00 / -0.64%
  • Shares traded64.60k
  • 1 Year change-24.80%
  • Beta0.7009
Data delayed at least 20 minutes, as of Dec 06 2022 06:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Events & Activity

  • 4553:TYO trading volume exceeds daily average by +15.83%
  • 4553:TYO price moved over -1.05% to 2,079.00

Key statistics

On Tuesday, Towa Pharmaceutical Co Ltd (4553:TYO) closed at 2,029.00, 0.74% above its 52-week low of 2,014.00, set on Nov 16, 2022.
52-week range
2,014.00Nov 16 20223,135.00Feb 18 2022
Markit short selling activity
Previous close2,042.00
Average volume75.06k
Shares outstanding51.52m
Free float26.85m
P/E (TTM)10.94
Market cap105.20bn JPY
EPS (TTM)186.62
Annual div (ADY)63.00
Annual div yield (ADY)3.09%
Div ex-dateSep 29 2022
Div pay-dateDec 01 2022
Next div ex-dateMar 30 2023
Next div pay-date--
Data delayed at least 20 minutes, as of Dec 06 2022 06:00 GMT.
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.